Review
Version 1
Preserved in Portico This version is not peer-reviewed
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Version 1
: Received: 27 July 2023 / Approved: 27 July 2023 / Online: 28 July 2023 (03:55:02 CEST)
A peer-reviewed article of this Preprint also exists.
Gonzalez Barca, E. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2023, 12, 7376. Gonzalez Barca, E. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2023, 12, 7376.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and biologically heterogeneous disease. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory (R/R) DLBCL. These agents include anti-CD19 chimeric antigen receptor T-cell therapies (CAR T-cells) and monoclonal antibodies as polatuzumab and tafasitamab. Nevertheless, despite the high efficacy of all these new therapies, there are still patients who do not respond or relapse, representing an unmet clinical need. This review describes new promising therapies that are under investigation to treat R/R DLBCL.
Keywords
diffuse large B-cell lymphoma. relapsed/refractory; therapy; efficacy; toxicity
Subject
Medicine and Pharmacology, Hematology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
